Castle Creek Pharmaceuticals names new chief medical officer and senior vice president of Research & Development
4 June 2019 -

Castle Creek Pharmaceuticals LLC, a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions, announced yesterday that it has named Mary Spellman, MD, as its new chief medical officer and senior vice president of Research & Development.

Dr Spellman is a board certified dermatologist with more than 30 years of clinical experience. Prior to joining Castle Creek, Dr Spellman managed the planning and execution of late-stage clinical programs as chief medical officer of Menlo Therapeutics. She was previously a medical consultant providing medical and safety support for multiple biopharmaceutical and device development companies, served as chief medical officer and senior vice president of Development at Revance Therapeutics, senior director of Medical Research in immunology at Biogen Idec, vice president of Dermatology Research at Connetics Corporation, and medical director at Novartis Pharmaceuticals.

Greg Wujek, chief executive officer of Castle Creek, said, 'We are pleased to welcome Dr Spellman to the Castle Creek team as we advance into late stage clinical development with our investigational diacerein ointment for the potential treatment of patients with epidermolysis bullosa simplex. Dr Spellman brings decades of experience in the biopharmaceutical industry and has supported the successful development of topical products. We look forward to her insights, not only as a leader in our industry but also as an accomplished practicing dermatologist.'